Table 1 Clinical cure or success in primary bacteremia patients receiving C/T
From: Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
Author, year | Study design | Pathogen type | Antibiotic resistance | Outcome definition | Time point | % (n/N) Reporting clinical cure or success |
|---|---|---|---|---|---|---|
Retrospective cohort studies | ||||||
 Bassetti et al., 2019 [12] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 17.8%, XDR: 50.5%, PDR infection: 2%a | Complete resolution of clinical signs and symptoms related to P. aeruginosa infection and lack of microbiological evidence of infection | – | 100% (6/6) |
 Diaz-Canestro et al., 2018 [23] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR: 10.3%, XDR: 86.2%a | Derived from clinical failure defined as persistent signs or symptoms of infection and positive culture after 7 days of treatment | – | 33.3% (1/3) |
 Elabor et al., 2018 [15] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Resolution of signs and symptoms present on diagnosis | – | 100% (4/4) |
 Gallagher et al., 2018 [17] | Retrospective cohort | Pseudomonas:100% (not further specified) | MDR infection: 100% | Defined as improved signs and symptoms from baseline to the end of therapy with fever reduction | – | 100% (6/6) |
 Haidar et al., 2017 [18] | Retrospective cohort (single patient) | P. aeruginosa:100% | MDR infection: 100% | Clinical failure was defined as attributable mortality due to P. aeruginosa, persistent signs or symptoms of infection or positive culture despite ≥ 7 days of C/T, or recurrent P. aeruginosa infection (recurrent signs and symptoms and recurrent culture positivity within 90 days)a | – | 100% (1/1)b |
 King et al., 2018 [11] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Improved symptoms, improved imaging where relevant, and fever reduction | – | 86.0% (6/7) |